March 24, 2022 01:28 PM EDTUpdated March 25, 09:50 AM

Roche comes up short in its attempt to hold off generic competition to Esbriet

Nicole DeFeudis

Editor

Roche’s blockbuster idiopathic pulmonary fibrosis drug Esbriet brings in more than $1 billion a year — and the Swiss pharma giant would like to keep it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche comes up short in its attempt to hold off generic competition to Esbriet

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Roche comes up short in its at­tempt to hold off gener­ic com­pe­ti­tion to Es­bri­et

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Roche comes up short in its attempt to hold off generic competition to Esbriet

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B